I det pivotale ICC- forsøg omfattede disse bivirkninger rødme/ hedeture (2, 3%), pruritus (2, 3%), udslæt (1, 5%) og urticaria (0, 8%).
Infusion-related adverse reactions have been reported with anidulafungin; in the pivotal ICC study, these included flushing/ hot flush (2.3%), pruritus (2.3%), rash (1.5%), and urticaria (0.8%).